Biotech

News

Clasp Therapeutics chief executive Rob Ross

Clasp emerges with $150m for safer T-cell engagers

Clasp Therapeutics has burst onto the T-cell engager (TCE) scene with $150 million in funding for a platform that aims to improve the safety of the class, which is current

News

MS and fibrosis drug developer Contineum files $150m IPO

Contineum Therapeutics has become the latest biotech to file for an initial public offering (IPO) in the US, hoping to raise $150 million for its early clinical-stage cand

News

WuXi splits from BIO as trade body backs BIOSECURE Act

The Biotechnology Innovation Organization (BIO) has said it is parting company with Wuxi AppTec, while voicing support for US legislation that would block Chinese biotechs

News

Boundless Bio files IPO, and other biotech financings

Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.

News

University of Southampton scientist Prof Ali Tavassoli, who is Curve's chief scientific officer

UK biotech Curve swings £40.5m in Pfizer-backed round

Southampton, UK-based start-up Curve Therapeutics has completed a £40.5 million ($51 million) in Series A financing for its drug discovery platform that enables drug scree

Oncology